Results 211 to 220 of about 86,631 (266)

A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers. [PDF]

Saudi Pharm J
Sharma AK, Rastogi S, Ali F, Yadav AP, Goyal RK.   +4 more
europepmc   +1 more source

Rationale and Design of a Randomized, Open-Label, Parallel-Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT-HT). [PDF]

J Clin Hypertens (Greenwich)
Kario K, Katsuya T, Shimosawa T, Taguchi T, Tanabe A, Ohishi M, ESCORT‐HT investigators.   +6 more
europepmc   +1 more source

ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation. [PDF]

Cardiol Ther
Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh MA, Farag N, Guindy R, Bendary A, Nayel AME, Shawky A, Khairy A, Mortada A, Zarif B, Badran H, Khorshid H, Mahmoud K, Said K, Leon K, Abdelsabour M, Tawfik M, Abdelmegid MAF, Koriem M, Loutfi M, Wadie M, Elnoamany M, Sadaka M, Seleem M, Zahran M, Amin OA, Elkaffas S, Ayad S, Kilany WE, Ammar W, Elawady W, Elhammady W, Abdelhady Y.   +35 more
europepmc   +1 more source

Angiotensin receptor blockers and pregnancy.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1998
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nitrosamine Impurities in Angiotensin Receptor Blockers

Cardiology in Review, 2020
Nitrosamines are known carcinogens which have been recently discovered in several angiotensin receptor blockers (ARBs). This led to the recall of valsartan in the United States in 2018, and afterward, the recall of other ARBs as well as unrelated medications (e.g., ranitidine).
Emily A, Shephard, James J, Nawarskas
openaire   +2 more sources

Drug interactions with angiotensin receptor blockers

Expert Opinion on Drug Safety, 2005
Many patients with high blood pressure receive multiple medications for hypertension and other conditions, placing them at risk for adverse drug interactions. Additionally, as the prevalence of hypertension increases with age, factors like greater frailty, comorbidity of the elderly requiring polypharmacy, and reduced hepatic and renal clearance rates ...
Steffen, Böhler, David, Pittrow, Peter, Bramlage, Wilhelm, Kirch   +3 more
openaire   +2 more sources

Fimasartan: A New Angiotensin Receptor Blocker

Drugs, 2016
Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one derivative of losartan with the imidazole ring replaced, which enables higher potency and longer duration than losartan. Fecal elimination and biliary excretion are the predominant elimination pathways of
Hae-Young, Lee, Byung-Hee, Oh
openaire   +2 more sources

Angiotensin receptor blockers in diabetic nephropathy

Current Diabetes Reports, 2001
Where shall we place angiotensin receptor blockers in the scheme of the prevention of diabetic nephropathy? Only the results of a large, randomized double-blind trial with a comparable and appropriate alternative would prove therapeutic efficacy. The results of several trials with angiotensin-converting enzyme (ACE) inhibitors have proven them to be ...
D A, Price, N K, Hollenberg
openaire   +2 more sources

Angiotensin Receptor Blockers for Management of Hypertension

Southern Medical Journal, 2010
The renin-angiotensin-aldosterone system (RAAS) plays a major role in blood pressure regulation and is thus an important therapeutic target in the management of hypertension. Angiotensin receptor blockers (ARBs), which interrupt RAAS overactivity by blocking a specific receptor that mediates the pathogenic activity of angiotensin II, represent a major ...
Daniel F, Catanzaro, William H, Frishman
openaire   +2 more sources